

MATERIALS LICENSE

Pursuant to the Atomic Energy Act of 1954, as amended, the Energy Reorganization Act of 1974 (Public Law 93-438), and Title 10, Code of Federal Regulations, Chapter I, Parts 30, 31, 32, 33, 34, 35, 36, 39, 40, and 70, and in reliance on statements and representations heretofore made by the licensee, a license is hereby issued authorizing the licensee to receive, acquire, possess, and transfer byproduct, source, and special nuclear material designated below; to use such material for the purpose(s) and at the place(s) designated below; to deliver or transfer such material to persons authorized to receive it in accordance with the regulations of the applicable Part(s). This license shall be deemed to contain the conditions specified in Section 183 of the Atomic Energy Act of 1954, as amended, and is subject to all applicable rules, regulations, and orders of the Nuclear Regulatory Commission now or hereafter in effect and to any conditions specified below.

<p>Licensee</p> <p>1. Kaiser Foundation Hospital Diagnostic Imaging Department</p> <p>2. 3288 Moanalua Road Honolulu, Hawaii 96819</p>	<p>In accordance with letter dated May 10, 2012</p> <p>3. License number 53-05379-01 is amended in its entirety to read as follows:</p> <p>4. Expiration date April 30, 2015</p> <p>5. Docket No. 030-03546 Reference No.</p>	
<p>6. Byproduct, source, and/or special nuclear material</p> <p>A. Any byproduct material permitted by 10 CFR 35.100</p> <p>B. Any byproduct material permitted by 10 CFR 35.200</p> <p>C. Any byproduct material permitted by 10 CFR 35.300</p> <p>D. Iodine-125 permitted by 10 CFR 35.1000</p>	<p>7. Chemical and/or physical form</p> <p>A. Any</p> <p>B. Any</p> <p>C. Any</p> <p>D. Liquid as Proxima Therapeutics, Inc. Iotrex™</p>	<p>8. Maximum amount that licensee may possess at any one time under this license</p> <p>A. As needed</p> <p>B. As needed</p> <p>C. 6 curies total (not to exceed 200 ± 10 millicuries per container)</p> <p>D. 5 curies total</p>
<p>9. Authorized use:</p> <p>A. Any uptake, dilution and excretion study permitted by 10 CFR 35.100.</p> <p>B. Any imaging and localization study permitted by 10 CFR 35.200.</p> <p>C. Any use permitted by 10 CFR 35.300.</p> <p>D. For use in the Proxima Therapeutics' GliaSite® Radiation therapy system permitted by 10 CFR 35.1000.</p>		

CONDITIONS

10. Licensed material may be used or stored only at the licensee's facilities located at 3288 Moanalua Road, Honolulu, Hawaii.

MATERIALS LICENSE SUPPLEMENTARY SHEET

License Number
53-05379-01

Docket or Reference Number
030-03546

Amendment No. 70

11. The Radiation Safety Officer for this license is Brian T. Oyadomari, M.S.
12. Licensed material is only authorized for use by, or under the supervision of:
- A. Individuals permitted to work as an authorized user, authorized nuclear pharmacist, and/or authorized medical physicist in accordance with 10 CFR 35.13 and 35.14.
- B. The following individuals are authorized users for the material and medical uses indicated:

Authorized Users

Material and Use

Peter Abcarian, M.D.	35.100; 35.200
Frederick T. Borts, M.D.	35.100; 35.200
Rickie A. Broadfoot, M.D.	35.100; 35.200
Bradford S. Burton, M.D.	35.100; 35.200
Felix Lee Song, M.D.	35.100; 35.200
Thomas G. Mahon, M.D.	35.100; 35.200; oral administration of sodium iodide I-131
Amy H. Martin, M.D.	35.100; 35.200
Ramana B. Muthyala, M.D.	35.100; 35.200
Marie S. Noitakis, M.D.	35.100; 35.200
Stein Rafto, M.D.	35.100; 35.200
Katrena U. Wade Kennedy, M.D.	35.100; 35.200
John T. Watabe, M.D.	35.100; 35.200
Decha Intaraprasong, M.D.	35.100; 35.200; 35.300
Daniel C. Henshaw, M.D.	35.100; 35.200; 35.300
Steven W. Hong, M.D.	35.100; 35.200; 35.300
Alison M. Shibuya, M.D.	35.100; 35.200; 35.300
Chung Ta Hsin, M.D.	35.100; 35.200; 35.300
Samuel M. H. Wu, M.D.	35.100; 35.200; 35.300
Vincent Brown, M.D.	35.1000 (I-125 in GliaSite radiation therapy system)
Paul DeMare, M.D.	35.1000 (I-125 in GliaSite radiation therapy system)
Thanh Huynh, M.D.	35.1000 (I-125 in GliaSite radiation therapy system)
Christina Liu, M.D.	35.1000 (I-125 in GliaSite radiation therapy system)
Mitchell A. Moy, M.D.	35.100; 35.200; oral administration of sodium iodide I-131 in quantities less than or equal to 33 millicuries
Calvin B. Delaplain, M.D.	35.100; 35.200; 35.300
David Kho, M.D.	35.100; 35.200; oral administration of sodium iodide I-131

**MATERIALS LICENSE
SUPPLEMENTARY SHEET**License Number
53-05379-01Docket or Reference Number
030-03546

Amendment No. 70

13. For sealed sources not associated with 10 CFR Part 35 use, the following conditions apply:
- A. Sealed sources shall be tested for leakage and/or contamination at intervals not to exceed the intervals specified in the certificate of registration issued by the U.S. Nuclear Regulatory Commission under 10 CFR 32.210 or under equivalent regulations of an Agreement State.
 - B. Notwithstanding Paragraph A of this Condition, sealed sources designed to primarily emit alpha particles shall be tested for leakage and/or contamination at intervals not to exceed 3 months.
 - C. In the absence of a certificate from a transferor indicating that a leak test has been made within the intervals specified in the certificate of registration issued by the U.S. Nuclear Regulatory Commission under 10 CFR 32.210 or under equivalent regulations of an Agreement State, prior to the transfer, a sealed source received from another person shall not be put into use until tested and the test results received.
 - D. Sealed sources need not be tested if they contain only hydrogen-3; or they contain only a radioactive gas; or the half-life of the isotope is 30 days or less; or they contain not more than 100 microcuries of beta- and/or gamma-emitting material or not more than 10 microcuries of alpha-emitting material.
 - E. Sealed sources need not be tested if they are in storage and are not being used; however, when they are removed from storage for use or transferred to another person and have not been tested within the required leak test interval, they shall be tested before use or transfer. No sealed source shall be stored for a period of more than 10 years without being tested for leakage and/or contamination.
 - F. The leak test shall be capable of detecting the presence of 0.005 microcurie (185 becquerels) of radioactive material on the test sample. If the test reveals the presence of 0.005 microcurie (185 becquerels) or more of removable contamination, a report shall be filed with the U.S. Nuclear Regulatory Commission in accordance with 10 CFR 30.50(c)(2), and the source shall be removed immediately from service and decontaminated, repaired, or disposed of in accordance with Commission regulations. The report shall be filed within 5 days of the date the leak test result is known with the U.S. Nuclear Regulatory Commission, Region IV, 1600 East Lamar Boulevard, Arlington, Texas 76011-4511, ATTN: Director, Division of Nuclear Materials Safety. The report shall specify the source involved, the test results, and corrective action taken.
 - G. Tests for leakage and/or contamination, including leak test sample collection and analysis, shall be performed by the licensee or by other persons specifically licensed by the U.S. Nuclear Regulatory Commission or an Agreement State to perform such services.
14. The licensee shall conduct a physical inventory every 6 months, or at other intervals approved by the U.S. Nuclear Regulatory Commission, to account for all source s and/or devices received and possessed under the license. Records of inventories shall be maintained for 5 years from the date of each inventory and shall include the radionuclides, quantities, manufacturer's name and model numbers, and the date of the inventory.

**MATERIALS LICENSE
SUPPLEMENTARY SHEET**License Number
53-05379-01Docket or Reference Number
030-03546

Amendment No. 70

15. Sealed sources or detector cells containing licensed material shall not be opened or sources removed from source holders by the licensee.
16. The licensee is authorized to transport licensed material in accordance with the provisions of 10 CFR Part 71, "Packaging and Transportation of Radioactive Material."
17. Except as specifically provided otherwise in this license, the licensee shall conduct its program in accordance with the statements, representations, and procedures contained in the documents, including any enclosures, listed below. This license condition applies only to those procedures that are required to be submitted in accordance with the regulations. Additionally, this license condition does not limit the licensee's ability to make changes to the radiation protection program as provided for in 10 CFR 35.26. The U.S. Nuclear Regulatory Commission's regulations shall govern unless the statements, representations, and procedures in the licensee's application and correspondence are more restrictive than the regulations.
- A. Application dated November 10, 2004 (ML043410107)
- B. Letter dated January 12, 2005
- C. Letter dated February 3, 2005
- D. E-mails dated February 9, 2005
- E. Letter dated March 24, 2005 (ML051010169)
- F. Letter dated November 17, 2011 (ML11335A037)



FOR THE U.S. NUCLEAR REGULATORY COMMISSION

Date July 31, 2012By /RA/

Roberto J. Torres, Senior Health Physicist
Nuclear Materials Safety Branch B
Region IV
Arlington, Texas 76011-4511